Catalent

CTLT · NYSE

Price unavailable right now.

No price history for this range.

CTLT analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Dec 14, 2024

Bull case

Catalent reported a total revenue of $1,301 million for the quarter, marking a 23.3% year-over-year increase, driven primarily by higher-than-expected biologics revenue of $605 million. The company achieved adjusted EBITDA of $305 million, representing a 23.4% margin, which exceeded both internal and consensus estimates, while adjusted EPS reached $0.65, significantly above expectations. Catalent's strategic focus on expanding its capabilities in the high-growth biologics segment and investments in gene and cell therapy, along with the growth in biopharma R&D spending and the trend toward outsourcing, position it to capitalize on favorable long-term industry dynamics.

Bear case

Catalent faces multiple financial risks that contribute to a negative outlook for its stock, including potential declines in productivity and underutilized capacity that could pressure profit margins. A sustained slowdown in biotech funding is anticipated to lead to reduced activity levels among drug developers, compounded by inflationary pressures that may dampen consumer discretionary spending and demand for consumer health products. Additionally, quality assurance issues identified by regulatory agencies could not only cause operational delays but also tarnish Catalent's reputation, creating further headwinds for the company.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.